Thorac Cardiovasc Surg 2013; 61(07): 575-580
DOI: 10.1055/s-0033-1347294
Original Cardiovascular
Georg Thieme Verlag KG Stuttgart · New York

Strategies for Endovascular Aortic Repair in Aortobronchial and Aortoesophageal Fistulas

Bernhard Dorweiler
1   Division of Vascular Surgery, Department of Cardiothoracic and Vascular Surgery, University Medical Center, Johannes-Gutenberg University, Mainz, Germany
,
Ernst Weigang
1   Division of Vascular Surgery, Department of Cardiothoracic and Vascular Surgery, University Medical Center, Johannes-Gutenberg University, Mainz, Germany
,
Friedrich Duenschede
1   Division of Vascular Surgery, Department of Cardiothoracic and Vascular Surgery, University Medical Center, Johannes-Gutenberg University, Mainz, Germany
,
Michael Bernhard Pitton
2   Department of Radiology, University Medical Center, Johannes-Gutenberg University, Mainz, Germany
,
Christoph Dueber
2   Department of Radiology, University Medical Center, Johannes-Gutenberg University, Mainz, Germany
,
Christian-Friedrich Vahl
1   Division of Vascular Surgery, Department of Cardiothoracic and Vascular Surgery, University Medical Center, Johannes-Gutenberg University, Mainz, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

11. März 2013

29. April 2013

Publikationsdatum:
04. Juli 2013 (online)

Preview

Abstract

Objective To report our experience of thoracic endovascular aortic repair (TEVAR) for acute bleeding originating from the thoracic aorta in patients with aortobronchial fistula (ABF) or aortoesophageal fistula (AEF).

Patients and Methods A total of nine patients (three woman) were treated from September 1995 to March 2012 by TEVAR for ABF (n = 5) and AEF (n = 4). The implants (N = 14) were introduced with fluoroscopic guidance via the aorta (n = 1), the iliac (n = 2), or femoral (n = 11) artery, respectively.

Results All aortic lesions could be sealed successfully. Perioperative morbidity was 0% in the ABF group and 50% (2 of 4) in the AEF group and no procedure-related morbidity was noted except one patient who received aortofemoral reconstruction because of iliac occlusive disease. After an overall mean follow-up of 56 months, three patients of the ABF group are alive and well and two patients died of nonrelated cause. Of the AEF group, one patient is alive after 22 months, and one died from metastasized esophageal cancer after 7 months.

Conclusion TEVAR is a safe and reliable procedure in the management of ABF. For AEF, TEVAR provides a successful first-line treatment to seal the fistula and control bleeding. However, prognosis is limited by the esophageal lesion and by ongoing mediastinitis/sepsis.